Two Sigma Securities LLC Increases Holdings in Boston Scientific Corporation $BSX

Key Points

• Two Sigma Securities increased its Boston Scientific stake by 261.3% in the second quarter, bringing its holdings to 98,200 shares valued at approximately $4.19 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific exceeded quarterly expectations with $0.86 EPS and $5.44 billion in revenue, while revenue rose 7.5% year over year. The company issued third-quarter EPS guidance of $0.80–$0.82 and full-year guidance of $3.28–$3.32.
• The company authorized a $5 billion share-buyback program, covering up to 6.4% of outstanding shares; insiders also purchased 194,522 shares worth about $9.4 million over the past three months. Analysts maintain a “Moderate Buy” consensus with a $71.62 average price target.

Two Sigma Securities LLC raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 261.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 98,200 shares of the medical equipment provider's stock after acquiring an additional 71,019 shares during the quarter. Two Sigma Securities LLC's holdings in Boston Scientific were worth $4,191,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. CYBER HORNET ETFs LLC boosted its holdings in Boston Scientific by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider's stock valued at $391,000 after purchasing an additional 132 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management raised its holdings in Boston Scientific by 4.7% during the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider's stock worth $294,000 after purchasing an additional 139 shares in the last quarter. Northwestern Mutual Investment Management Company LLC raised its holdings in Boston Scientific by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider's stock worth $4,516,000 after purchasing an additional 140 shares in the last quarter. Kingsview Wealth Management LLC lifted its position in shares of Boston Scientific by 2.4% during the 4th quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider's stock worth $578,000 after buying an additional 142 shares during the last quarter. Finally, Fairfield Financial Advisors LTD boosted its holdings in shares of Boston Scientific by 2.9% in the 4th quarter. Fairfield Financial Advisors LTD now owns 5,366 shares of the medical equipment provider's stock valued at $512,000 after buying an additional 150 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $46.82 on Monday. The stock has a market capitalization of $67.85 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The stock's 50-day moving average price is $46.56 and its 200 day moving average price is $56.53. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm's revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has authorized a share buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company's leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

BSX has been the topic of several research reports. Bank of America dropped their price objective on Boston Scientific from $105.00 to $68.00 and set a "buy" rating on the stock in a report on Monday, May 18th. Oppenheimer decreased their target price on Boston Scientific from $90.00 to $85.00 and set an "outperform" rating for the company in a research report on Monday, July 27th. Raymond James Financial restated an "outperform" rating and set a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Finally, Mizuho decreased their price objective on Boston Scientific from $90.00 to $70.00 and set an "outperform" rating for the company in a report on Wednesday, July 15th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $71.62.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of the company's stock in a transaction on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source